{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-114926","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.082563+00:00","generated_at":"2026-05-22T07:23:09.342655+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Catalyst Q1 revenues $141.4M (+43.6% YoY); GAAP EPS $0.45; reaffirms FY outlook","bullets":["Total product revenue $141.4M, up 43.6% YoY; FIRDAPSE $83.7M (+25.3%), AGAMREE $22.0M (from $1.2M).","GAAP net income $56.7M ($0.45 diluted EPS); Non-GAAP net income $86.6M ($0.68 diluted EPS).","Cash and equivalents $580.7M as of March 31, 2025; no debt.","Reaffirms full-year 2025 total revenue guidance of $545M–$565M.","AGAMREE commercial launch momentum with 1,777.5% YoY revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-114926","json":"https://secwatch.observer/filing/0001193125-25-114926.json","markdown":"https://secwatch.observer/filing/0001193125-25-114926.md","text":"https://secwatch.observer/filing/0001193125-25-114926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/0001193125-25-114926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/d892793d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:23:09.342655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}